Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) is now available.
Biocytogen Pharmaceuticals has announced the determination of the offer size and price for its A Share Offering, with plans to issue 47,500,000 new A Shares at RMB26.68 per share. This strategic move, following preliminary price consultations, aims to enhance the company’s market presence and leverage its fundamentals, market conditions, and industry valuations, potentially impacting its operations and positioning within the biotechnology sector.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company based in China, focusing on innovative drug research and development. The company is involved in the biotechnology industry, primarily offering products and services related to pharmaceuticals and biotechnological advancements.
Average Trading Volume: 525,388
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.29B
See more insights into 2315 stock on TipRanks’ Stock Analysis page.